Literature DB >> 7693285

Endothelin-induced contraction and mediator release in human bronchus.

D W Hay1, W C Hubbard, B J Undem.   

Abstract

1. To elucidate the role of acetylcholine and various autacoids in endothelin-1 (ET-1)-induced contraction in human bronchus, the effects of various receptor antagonists were examined. In addition, the ability of ET-1 to stimulate the release of histamine, peptidoleukotrienes and prostanoids was determined. 2. ET-1 was a potent and effective contractile agonist in human bronchus, possessing similar potency and efficacy to leukotriene D4 (LTD4); EC50 (-log M): ET-1 = 7.76 +/- 0.09, n = 7; LTD4 = 8.46 +/- 0.53, n = 7; P > 0.2; maximum response (% 10 microM pre-carbachol): ET-1 = 103.8 +/- 17.4, n = 7; LTD4 = 95.5 +/- 9.3, n = 7; P > 0.6. 3. The cyclo-oxygenase inhibitor, sodium meclofenamate (1 microM) or the potent and selective thromboxane receptor antagonist, SQ 29,548 (1 microM) were without significant effect on ET-1 concentration-response curves. 4. In the presence of sodium meclofenamate (1 microM), the muscarinic receptor antagonist, atropine (1 microM), the platelet activating factor (PAF) receptor antagonist, WEB 2086 (1 microM) or the combination of the H1-histamine receptor antagonist, mepyramine (10 microM) and the leukotriene receptor antagonist, SK&F 104353 (10 microM), were without marked effect on ET-1 concentration-response curves. In addition, the combination of all four receptor antagonists did not antagonize ET-1-induced contraction. 5. ET-1 (0.3 microM) did not stimulate the release of histamine or immunoreactive leukotrienes from human bronchus. 6. ET-1 (0.3 microM) significantly stimulated the release of prostaglandin D2 (PGD2), 9alpha, 11beta PGF2 (PGD2 metabolite), PGE2, 6-keto PGF1alpha (PGI2 metabolite), PGF2alpha, and thromboxane B2 (TxB2) a lower concentration, 10 nM, was without effect on prostanoid release. The production of PGD2 was increased 7.5 fold, whereas the release of the other prostanoids was stimulated only about 1.6 to 2.7 fold.7. These data provide evidence that ET-1 elicits contraction of human isolated bronchus predominantly via a direct mechanism with no significant involvement of the release of acetylcholine, leukotrienes,histamine or PAF. Although ET-1 increased the release of several prostanoids they did not have a significant modulatory effect on the smooth muscle contraction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693285      PMCID: PMC2176013          DOI: 10.1111/j.1476-5381.1993.tb13822.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

2.  Similarity of endothelin to snake venom toxin.

Authors: 
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

3.  Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways.

Authors:  D W Hay; R M Muccitelli; S S Tucker; L M Vickery-Clark; K A Wilson; J G Gleason; R F Hall; M A Wasserman; T J Torphy
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

4.  Antigen-induced sulfidopeptide leukotriene release from the guinea pig superfused trachea.

Authors:  B J Undem; W C Pickett; G K Adams
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  An automated continuous-flow system for the extraction and fluorometric analysis of histamine.

Authors:  R P Siraganian
Journal:  Anal Biochem       Date:  1974-02       Impact factor: 3.365

7.  Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis.

Authors:  J Casals-Stenzel
Journal:  Immunopharmacology       Date:  1987-04

8.  Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinomas and normal human lung by capillary gas chromatography-negative ion chemical ionization mass spectrometry.

Authors:  W C Hubbard; C L Litterst; M C Liu; E R Bleecker; J C Eggleston; T L McLemore; M R Boyd
Journal:  Prostaglandins       Date:  1986-12

9.  Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

Authors:  J Casals-Stenzel
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

10.  Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.

Authors:  M L Ogletree; D N Harris; R Greenberg; M F Haslanger; M Nakane
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

View more
  11 in total

1.  Mechanisms of leukotriene D4-induced constriction in human small bronchioles.

Authors:  V A Snetkov; K J Hapgood; C G McVicker; T H Lee; J P Ward
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout mice.

Authors:  D W Hay; S A Douglas; Z Ao; R M Moesker; G J Self; P J Rigby; M A Luttmann; R G Goldie
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Time course of changes in ETB receptor density and function in tracheal airway smooth muscle during respiratory tract viral infection in mice.

Authors:  M J Carr; R G Goldie; P J Henry
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.

Authors:  D T Schmidt; N Watson; G Dent; E Rühlmann; D Branscheid; H Magnussen; K F Rabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

5.  The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle.

Authors:  C Ravenhall; E Guida; T Harris; V Koutsoubos; A Stewart
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

6.  Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1.

Authors:  Amy M Sutcliffe; Deborah L Clarke; Dawn A Bradbury; Lisa M Corbett; Jamie A Patel; Alan J Knox
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

7.  Endothelin-1-induced potentiation of human airway smooth muscle proliferation: an ETA receptor-mediated phenomenon.

Authors:  R A Panettieri; R G Goldie; P J Rigby; A J Eszterhas; D W Hay
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

8.  Novel small airway bronchodilator responses to rosiglitazone in mouse lung slices.

Authors:  Jane E Bourke; Yan Bai; Chantal Donovan; James G Esposito; Xiahui Tan; Michael J Sanderson
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

9.  Modulation of ET-1-induced contraction of human bronchi by airway epithelium-dependent nitric oxide release via ET(A) receptor activation.

Authors:  E Naline; C Bertrand; K Biyah; Y Fujitani; T Okada; A Bisson; C Advenier
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 10.  Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma.

Authors:  V H van der Velden
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.